文献速递临床试验与 GCP基础与转化研究

壳聚糖补充剂对非酒精性脂肪肝患者肝脏脂肪及代谢参数影响的随机对照试验方案

Effects of chitosan supplementation versus placebo on liver fat and metabolic parameters in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
PubMed 文献 · Trials · 2026-02-14

该方案为双盲、随机、安慰剂对照的II期临床试验,计划在伊朗招募60名经弹性成像诊断的肝脂肪变性成人,随机接受壳聚糖1.5 g/天或安慰剂8周,主要结局为弹性成像测定的肝脏脂肪含量变化。基于动物证据,预期壳聚糖可减少肝脏脂肪堆积、改善肝酶和代谢参数。

要点

  • 壳聚糖1.5 g/天干预8周,主要结局为弹性成像肝脏脂肪含量变化。
  • 纳入60名经弹性成像诊断的肝脂肪变性成人,随机双盲安慰剂对照。
  • 次要结局包括人体测量、肝酶、空腹血糖、血脂和胰岛素抵抗。

核心结论

  • 基于动物证据,壳聚糖补充剂预期可减少NAFLD患者肝脏脂肪堆积、改善肝酶水平和代谢参数。
  • 若试验证实,壳聚糖可能成为管理肝脂肪变性的有前景的辅助手段。

研究设计与样本

  • 双盲、随机、安慰剂对照的II期临床试验。
  • 计划从伊朗马什哈德Imam Reza医院胃肠病和肝病门诊招募60名经弹性成像诊断的肝脂肪变性成人。
  • 参与者随机接受壳聚糖1.5 g/天(500 mg胶囊,每日三次,餐后服用)或匹配安慰剂,持续8周。
  • 所有参与者均接受标准化饮食咨询。

关键数值与推荐

  • 主要结局:基线和第8周弹性成像测定的肝脏脂肪含量变化。
  • 次要结局:人体测量指标、肝酶、空腹血糖、血脂谱和胰岛素抵抗的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder affecting about one-third of the global population. It encompasses a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) and may progress to fibrosis and cirrhosis. Chitosan oligosaccharide (COS) has recently emerged as a potential therapeutic agent with antioxidant and anti-inflammatory properties; however, most evidence comes from animal studies. Further clinical research is therefore warranted to evaluate its efficacy in humans. METHOD: This double-blind, randomized, placebo-controlled phase II clinical trial will evaluate the effects of chitosan supplementation in patients with hepatic steatosis. Sixty eligible adults diagnosed by elastography will be recruited from the gastroenterology and liver clinic at Imam Reza Hospital, Mashhad, Iran. Participants will be randomly assigned to receive either 1.5 g/day of chitosan (500 mg capsules, taken three times daily after meals) or a matching placebo for eight weeks. All participants will receive standardized dietary counseling. Primary outcomes include changes in liver fat content measured by elastography at baseline and week 8. Secondary outcomes include alterations in anthropometric measures, liver enzymes, fasting glucose, lipid profile, and insulin resistance. CONCLUSION: Based on animal evidence, chitosan supplementation is expected to reduce hepatic fat accumulation, improve liver enzyme levels, and enhance metabolic parameters in patients with NAFLD. If confirmed, these findings could support the potential of chitosan as a promising adjunct for managing hepatic steatosis. TRIAL REGISTRATION: This study is registered on the Iranian Registry of Clinical Trials (IRCT20230522058260N1: https://www.irct.ir/trial/79063 ) and first release date of 8th March 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rouini M, Alimoradi H, Chamani A, et al. Effects of chitosan supplementation versus placebo on liver fat and metabolic parameters in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. Trials. 2026. PMID: 41689047. doi:10.1186/s13063-026-09504-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。